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J Sex MedBackground: Current treatments for erectile dysfunction (ED) have some limitations.
Aim: This study evaluated the efﬁcacy and tolerability of MED2005, a 0.2% glyceryl trinitrate topical gel,
formulated into an enhanced absorption topical delivery system (DermaSys), administered on demand, in the
treatment of ED.
Methods: This randomized, double-blinded, placebo-controlled, phase II crossover trial involved 232 men with
ED (231 treated, 230 assessed for efﬁcacy) and their partners. After a 4-week run-in period, patients were
randomized to 1 of 2 treatment sequences, MED2005-placebo or placebo-MED2005. Each treatment was given
for 4 weeks, separated by a 1-week washout interval. Efﬁcacy was assessed by the International Index of Erectile
Function (IIEF), the Sexual Encounter Proﬁle, a Global Assessment Questionnaire (GAQ), and speciﬁc
questions about the onset and offset of action and treatment preferences (patients and partners).
Outcomes: The primary outcome measure was the IIEF erectile function domain (IIEF-EF) score. Other
efﬁcacy assessments were secondary outcomes.
Results: The mean baseline IIEF-EF score was 17.1 (SD ¼ 5.7), and this increased to 19.6 (SD ¼ 7.5) after
MED2005 treatment and 18.5 (SD ¼ 6.7) after placebo (P ¼ .0132). Overall, 23.1% of patients showed a
clinically relevant (4-point) increase in IIEF-EF scores after treatment with MED2005 only compared with
14.5% who responded after MED2005 and placebo, 14.0% who responded after placebo only, and 48.4% who
did not respond after either treatment (P ¼ .0272). MED2005 also was associated with signiﬁcant improvements
compared with placebo in the other IIEF domains, and this was consistent with patients’ and partners’ responses
to the GAQ. For all assessments, signiﬁcant effects of MED2005 were seen primarily in patients with mild ED.
The start of erection was noticed within 5 and 10 minutes in 44.2% and 69.5%, respectively, of all intercourse
attempts with MED2005. Patients and partners showed signiﬁcant preferences for MED2005 over placebo. The
most commonly reported adverse events during MED2005 treatment were headache (patients, n ¼ 18 [7.9%];
partners, n ¼ 3 [1.3%]) and nasopharyngitis (patients, n ¼ 13 [5.7%]; partners, n ¼ 2 [0.9%]).
Clinical Implications: Theseﬁndings suggest that topical glyceryl trinitrate could be a useful treatment option inED.
Strengths and Limitations: Strengths of this study include the use of a validated outcome measure. Limita-
tions include the use of only 1 dosage.
Conclusion: Further studies are warranted to investigate the efﬁcacy of topical glyceryl trinitrate to include
higher doses, thereby improving clinical signiﬁcance, especially in cases of moderate and severe ED. Ralph DJ,
Eardley I, Taubel J, et al. Efﬁcacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in
the Treatment of Erectile Dysfunction: A Randomized Crossover Study. J Sex Med 2018;15:167e175.
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Erectile dysfunction (ED) is deﬁned as the inability to initiate
and/or maintain an erection that is satisfactory for sexual inter-
course.1,2 ED, which increases with age, has a signiﬁcant impact
on quality of life for the man and his partner.3e7
Phosphodiesterase type 5 (PDE5) inhibitors have revolution-
ized the management of ED for some men but have certain limi-
tations. They have to be taken daily or sufﬁciently in advance of
sexual intercourse to allow effective circulating drug concentra-
tions to be attained, thus hindering spontaneity. PDE5 inhibitors
have a relatively long half-life that vastly exceeds the usual duration
of sexual intercourse. They also are associated with adverse effects
such as headache, back pain, and visual disturbances,1,8 which can
lead to discontinuation. Moreover, pre-existing comorbidities,
such as unstable angina, and use of nitrates are contraindicated.
Other non-oral local treatment strategies, such as intracavernosal
injections, penile implants, or vacuum erection devices, also have
signiﬁcant limitations.1,8 Topical therapy offers potential advan-
tages for the treatment of ED, including non-invasiveness, the
potential for a fast onset of action, ease of use, a lack of interaction
with food or moderate alcohol intake, and good tolerability. Their
use could be incorporated into sexual foreplay, increasing the level
of intimacy between couples.
Nitric oxide (NO) plays a key role in initiating and main-
taining penile erection, because it relaxes cavernosal smooth
muscle, thereby compressing the penile veins and preventing
local venous return.8,9 Therefore, NO donors, such as glyceryl
trinitrate (GTN), could be effective in the treatment of ED.
MED2005 is a topical gel containing 0.2% (w/w) GTN,
which is under development for the treatment of ED. This
product uses the MED2002 topical gel formulation and
incorporates DermaSys (Futura Medical plc, Guildford, UK)
technology to facilitate rapid absorption (to minimize any
potential partner transference) and effective delivery of GTN
across the skin.10 Pharmacokinetic and pharmacodynamic
studies with this preparation suggest that a GTN dose of 0.6 mg
(0.2%, w/w) produces changes in penile blood ﬂow consistent
with erection, with a relatively short half-life. This creates the
ideal proﬁle needed for spontaneous sexual intercourse, which
generally lasts for several minutes rather than hours. This also
suggests a favorable safety proﬁle (unpublished data). This article
reports on a randomized phase II trial evaluating the efﬁcacy and
safety of MED2005 (0.2%, w/w) in men with ED.METHODS
The trial was a randomized, double-blinded, placebo
controlled, crossover study performed at 1 site in the UnitedKingdom and 3 sites in Poland. It was conducted in accordance
with the ethical principles of the Declaration of Helsinki and the
International Council for Harmonization guidelines for Good
Clinical Practice. The protocol was approved by independent
ethics committees at all participating centers. The study is
registered with ClinicalTrials.gov (NCT02495467).
The primary objective of the study was to evaluate the efﬁcacy
of MED2005 vs placebo in men with a conﬁrmed diagnosis of
ED according to the International Index for Erectile Function
erectile function domain (IIEF-EF).11,12 Secondary objectives
were to evaluate the efﬁcacy of MED2005 using other IIEF
domains and other questionnaires, in addition to subjective
measures of onset and offset of action, and to assess the safety
and tolerability of MED2005 in patients and their partners.Patients
Men 18 to 70 years old were eligible for inclusion in the study
if they had a conﬁrmed diagnosis of ED (deﬁned as the inability
to achieve and/or maintain a penile erection sufﬁcient for satis-
factory sexual performance13) for at least 3 months and a score
no higher than 25 points on IIEF questions 1 to 5 and question
15 (IIEF-EF). In addition, they were required to have been in a
continuous heterosexual relationship for at least 6 months before
screening and to have had residual erectile function, as assessed
by the IIEF, during the previous 3 months. Adequate contra-
ception was to be used throughout the study period if the
patient’s female partner was of childbearing potential.
Patients were excluded if they had signiﬁcant medical or
psychiatric conditions or if they had active and symptomatic
urinary tract infection at screening. Other exclusion criteria
included anatomic abnormalities that could signiﬁcantly impair
erectile function; primary hypoactive sexual desire or a history of
hypogonadism; previous radical prostatectomy or surgery for
Peyronie disease; concurrent treatment with PDE5 inhibitors or
NO donors such as GTN, isosorbide dinitrate, or amyl or butyl
nitrite; hypotension; migraine or a history of recurrent headache;
evidence of alcoholism or drug abuse within the previous
12 months; or conﬁrmed positive results from a urine drugs-of-
abuse screen.
Written informed consent was obtained from all patients and
their partners before inclusion in the study.Study Procedures
Eligible patients entered a 4-week baseline run-in period,
during which they refrained from using any ED therapy,
and were required to attempt sexual intercourse on at least
4 occasions. On completion of this period, eligible patients
were randomized 1:1 to 1 of 2 treatment sequences,J Sex Med 2018;15:167e175
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numbers were allocated sequentially according to a computer-
generated randomization list. The 2 treatments were given for
4 weeks, separated by a 1-week treatment-free period. To
maintain blinding, MED2005 and placebo gels were identical in
appearance and were supplied in identical packaging.
During each treatment period, patients and their partners
were required to attempt sexual intercourse, using their study
medication, on at least 4 occasions. The study medication was
administered by massaging a pea-size amount [containing 0.2%
(w/w) GTN] into the glans of the penis using a ﬁnger for at least
15 seconds immediately before intercourse; this could be done by
the patient or partner (with no requirement to remove any re-
sidual gel or wait for any period before sexual intercourse), and all
patients and partners were shown how to apply the gel.
Concomitant treatment with other ED therapies, androgens, or
NO donors was prohibited throughout the study. However, there
were no restrictions on food or alcohol intake during the study.
The efﬁcacy of MED2005 was assessed by the IIEF at the end
of the run-in period and each treatment period and by the Sexual
Encounter Proﬁle (SEP) after each intercourse attempt during
run-in and treatment. Only patients completed the IIEF,
whereas separate SEPs were completed by patients and their
partners. In addition, patients and their partners completed a
Global Assessment Questionnaire (GAQ) at the end of each
treatment period. Speciﬁc questions on the onset and offset of
action of treatment were asked in conjunction with the SEP after
each intercourse attempt, and overall treatment preference was
assessed at the end of the study. The primary efﬁcacy end point
was the IIEF-EF score. Secondary end points were other IIEF
domain scores, SEP questions, onset-offset questions, GAQ as-
sessments, and overall treatment preference.
Safety and tolerability were assessed by monitoring adverse
events throughout the study and by physical examination,
measurement of vital signs, and clinical laboratory investigations
at various times during the study.
Statistical Methods
Efﬁcacy analyses were performed on the full analysis set,
consisting of randomized patients who had at least 1 efﬁcacy
assessment in a treatment period during which an intercourse
attempt was reported. Analyses were performed using linear
mixed models, which assumed that missing values were randomly
distributed, and were complemented using a last-observation-
carried-forward strategy. Safety analyses were based on the
safety set, consisting of all randomized patients who used their
medication at least once.
The primary efﬁcacy end point and other IIEF domains were
analyzed using a linear mixed model with treatment, period, and
sequence as ﬁxed effects, patient as a random effect, and baseline
(run-in) value as a covariate. In addition, the proportion of pa-
tients showing a minimally clinically important difference (4-
point increase deﬁned by Rosen et al11) in IIEF-EF score wasJ Sex Med 2018;15:167e175analyzed using the Prescott test. For each SEP question, a
generalized linear model was ﬁtted to the number of “yes” re-
sponses using a log-link function and a negative binomial dis-
tribution, with the log-transformed number of intercourse
attempts as an offset. Onset-offset questions were analyzed by
Wilcoxon ranks for each intercourse attempt, averaged across
each treatment period for each patient. The averaged ranked data
were analyzed using a linear mixed model. Responses to the
individual GAQ questions were analyzed by the Prescott test,
and the question on treatment preference was analyzed using a
2-sided binomial test comparing to a proportion of 0.5.
Prespeciﬁed subgroup analyses were performed in patients with
mild (IIEF-EF score ¼ 17e25), moderate (IIEF-EF score ¼
11e16), or severe (IIEF score 10) ED and in the combinedmild
and moderate ED subgroups (IIEF-EF score ¼ 11e25).
All statistical analyses were carried out using SAS 9.3 (SAS
Institute, Cary, NC, USA), with no adjustments for multiplicity.
P values less than .05 were considered signiﬁcant.
The sample size calculation was based on previous studies with
topical alprostadil, in which the mean changes from baseline in
IIEF-EF scores compared with placebo were 2.4 to 8.4.14
Assuming a mean difference in IIEF-EF scores between
MED2005 and placebo of 2.5 (SD ¼ 7.5), a sample size of 192
patients would provide 90% power with a 2-sided type I error
rate of 0.05.RESULTS
Of 392 patients screened, 232 were randomized; of these, 114
were randomized to the placebo-MED2005 treatment sequence
and 118 to the MED2005-placebo sequence (Figure 1). The
safety set consisted of 231 patients who used the medication at
least once. An additional patient was excluded from the full
analysis set because of no on-treatment efﬁcacy assessments.
2 patients in each sequence withdrew their consent before the
2nd treatment period and 3 patients (MED2005-placebo) were
not treated in period 2; overall, 225 patients completed the
study.
Baseline demographic and clinical characteristics of the
patients are presented in Table 1. The mean age of the patients
was 43 years (range ¼ 19e70), and the mean IIEF-EF score was
17.1 (SD ¼ 5.7).
The total number of intercourse attempts with MED2005 and
placebo was 1,003 and 984, respectively. The mean number of
intercourse attempts during each treatment period and with the
2 treatments was 4.4.Changes in IIEF-EF Scores
The mean IIEF-EF scores after treatment with MED2005 or
placebo were 19.6 (SD ¼ 7.5) and 18.5 (SD ¼ 6.7), respectively,
compared with a mean score during the run-in period of 17.1
(SD ¼ 5.7). The least squares mean treatment difference
Subjects screened
N=392
(N=72 PL, N=320 GBR)
Subjects randomised
N=232

























































Figure 1. Patient disposition. *1 patient completed visits in treatment period 1 but never sent back the investigational medical product. The
investigator’s comment was, “Reviewing online questionnaire it would appear that the volunteer has never used the [investigational medical
product].” Therefore, the subject was excluded from the safety set, FAS, and PP set. **Reasons leading to study discontinuation were
positive results from drugs-of-abuse testing. ***Within the safety set, 227 subjects (114 þ 113) received placebo and 229 subjects (117 þ
112) received MED2005. FAS ¼ full analysis set, GBR ¼ Great Britain (United Kingdom); PL ¼ Poland; PP ¼ per protocol.
170 Ralph et alfavoring MED2005 was 1.03 (95% CI ¼ 0.22e1.84, P ¼
.0132). MED2005 also was associated with signiﬁcant
improvements compared with placebo in IIEF-EF scores in the
subgroup of patients with mild ED and in the combined sub-
groups of patients with mild and moderate ED (Table 2,
Figure 2). No signiﬁcant improvement was noted in the mod-
erate and severe subgroups.
Overall, 51 of 221 patients (23.1%) showed an increase in
IIEF-EF scores of at least 4 points after treatment with
MED2005 only compared with 31 of 221 patients (14.0%) after
placebo only; 32 of 221 patients (14.5%) showed this increase
after the 2 treatments, and 107 of 221 (48.4%) did not show this
increase after either treatment. The difference between treat-
ments was statistically signiﬁcant (P ¼ .0272).Other IIEF Domains
In the overall study population, there were signiﬁcant treat-
ment differences favoring MED2005 in all other domains of the
IIEF (orgasmic function, P ¼ .012; sexual desire, P < .0001;
intercourse satisfaction, P ¼ .0055; overall satisfaction, P ¼ .001;
Figure 2).SEP Questionnaire
The proportions of patients answering “yes” to the 5 questions
of the SEP are presented in Table 3. In the overall studypopulation, there were no signiﬁcant treatment differences in
patients’ responses to SEP questions 1 to 3, but signiﬁcant (P <
.001) treatment differences favoring MED2005 were seen for
question 4 (“Were you satisﬁed with the hardness of your erec-
tion?”) and question 5 (“Were you satisﬁed overall with this
sexual experience?”).Onset and Offset of Action
In the overall study population, the start of erection was
noticed within 5, 10, and 20 minutes in 44.2%, 69.5%, and
75.5%, respectively, of all intercourse attempts with MED2005.
The corresponding respective ﬁgures with placebo were 42.0%,
69.5%, and 75.5%.
In the overall study population, there was no signiﬁcant
treatment difference in the time to offset of erection. Partners’
responses to the onset-offset questions were similar to the pa-
tients’ responses.
Global Assessment Questionnaire
For GAQ question 1 (“Has the treatment you have been
taking improved your erectile function?”), 58 of 216 (26.9%)
answered “yes” for MED2005 only, 20 of 216 (9.3%) for pla-
cebo only, 36 of 216 (16.7%) for the 2 treatments, and 102 of
216 (47.2%) for neither treatment (P < .0001). For question 2
(“If yes, has the treatment improved your ability to engage inJ Sex Med 2018;15:167e175
Table 1. Baseline demographic and clinical characteristics (safety set)*
Country
Overall (N ¼ 231)UK (n ¼ 177) Poland (n ¼ 54)
Age (y) 43.6 (15.0) 40.9 (10.9) 43.0 (14.2)
Body mass index (kg/m2) 26.7 (4.2) 26.3 (3.9) 26.6 (4.1)
Race
White 140 (79.1%) 54 (100.0%) 194 (84.0%)
Black or African American 17 (9.6%) 0 17 (7.4%)
Asian 9 (5.1%) 0 9 (3.9%)
Other 11 (6.2%) 0 11 (4.8%)
IIEF-EF score 16.0 (5.7) 20.7 (4.1) 17.1 (5.7)
IIEF-EF score by severity†
Mild ED (IIEF-EF score ¼ 17e25)‡ 90 (51.1%) 44 (81.5%) 134 (58.3%)
IIEF-EF score 20.7 (2.3) 22.4 (1.6) 21.3 (2.2)
Moderate ED (IIEF-EF score ¼ 11e16) 46 (26.1%) 9 (16.7%) 55 (23.9%)
IIEF-EF score 14.2 (1.5) 13.9 (1.5) 14.1 (1.5)
Severe ED (IIEF-EF  10) 40 (22.7%) 1 (1.9%) 41 (17.8%)
IIEF-EF score 7.5 (1.7) 7.0 7.5 (1.7)
Mild and moderate ED (IIEF-EF score ¼ 11e25) 136 (77.3%) 53 (98.1%) 189 (82.2%)
IIEF-EF score 18.5 (3.7) 21.0 (3.6) 19.2 (3.8)
ED ¼ erectile dysfunction; IIEF-EF ¼ International Index of Erectile Function erectile function domain.
*Results are presented as mean (SD) or number (percentage).
†Baseline ED categories are reported for the full analysis set (n ¼ 230). 1 patient from the United Kingdom was excluded from the full analysis set; hence, the
percentages of patients in each category are based on sample of 176.
‡Includes mild ED (IIEF-EF score ¼ 22e25) and mild to moderate ED (IIEF-EF score ¼ 17e21).
Topical GTN in Treatment of Erectile Dysfunction 171sexual activity?”), when patients answering “no” to question 1
were assumed to have also answered “no” to this question, 52 of
216 patients (24.1%) answered “yes” for MED2005 only, 21 of
216 (9.7%) for placebo only, 33 of 216 (15.3%) for the 2
treatments, and 110 of 216 (50.9%) for neither treatment (P ¼
.0003 for difference between treatments). Partners’ responses
were consistent with those of the patients.
Overall Treatment Preference
Overall, 91 of 225 patients (40.4%) expressed a preference for
MED2005, 50 of 225 (22.2%) for placebo, and 84 of 225 (37.3%)
for neither (P¼ .0007).Correspondingﬁgures for the partners were
38.0%, 22.2%, and 39.8%, respectively (P ¼ .003).
Tolerability
Overall, 80 adverse events occurred in 55 of 229 patients
(24.0%) during treatment with MED2005, and 50 occurred inTable 2. Mean (SD) IIEF-EF scores (full analysis set)
Run-in period MED2005
All patients (n ¼ 230) 17.1 (5.7) 19.6 (7.5)
Mild ED (n ¼ 134)* 21.3 (2.2) 23.1 (5.4)
Moderate ED (n ¼ 55) 14.1 (1.5) 16.7 (6.4)
Severe ED (n ¼ 41) 7.5 (1.7) 11.7 (7.6)
Mild and moderate ED (n ¼ 189) 19.2 (3.8) 21.2 (6.4)
ED ¼ erectile dysfunction; IIEF-EF ¼ International Index of Erectile Function er
*Includes mild ED (IIEF-EF score ¼ 22e25) and mild to moderate ED (IIEF-EF
J Sex Med 2018;15:167e17542 of 227 patients (18.5%) receiving placebo gel (Table 4).
Among partners, 7 adverse events occurred in 7 of 229 women
(3.1%) with MED2005 and 3 occurred in 3 of 227 women
(1.3%) with placebo. Of the adverse events considered related to
treatment, 34 occurred in 24 of 229 patients (10.5%) and
4 occurred in 4 of 229 partners (1.7%) during MED2005
treatment compared with 9 occurring in 8 of 227 (3.5%) and
1 occurring in 1 of 227 (0.4%), respectively, during placebo
treatment. In patients and partners, the most commonly reported
adverse events during MED2005 treatment were headache
(patients, n ¼ 18 of 229 [7.9%]; partners, n ¼ 3 of 229 [1.3%])
and nasopharyngitis (patients, n ¼ 13 of 229 [5.7%]; partners,
n ¼ 2 of 229 [0.9%]). No other adverse event occurred in more
than 5 patients or more than 1 partner. No cases of priapism
were reported during the study. All except 2 adverse events,
which occurred during MED2005 treatment, were mild or
moderate in severity; the 2 severe adverse events (gastroenteritisPlacebo LS mean difference (95% CI) P value
18.5 (6.7) 1.03 (0.22e1.84) .0132
21.3 (5.0) 1.81 (0.93e2.68) <.0001
17.1 (5.3) 0.099 (1.89 to 1.69) .91
11.3 (7.5) 0.057 (2.58 to 2.70) .97
20.1 (5.4) 1.18 (0.38e1.99) .0043






















































LS mean treatment difference (MED2005 – placebo) with 95% CI
1 2
Figure 2. Panels A to E show forest plots of LS mean treatment differences (MED2005 vs placebo) in erectile function, orgasmic
function, sexual desire, intercourse satisfaction, and overall satisfaction domains, respectively, of the International Index of Erectile
Function. Horizontal lines indicate 95% CI. International Index of Erectile Function erectile function domain scores are 17 to 25 for mild ED, 11
to 16 for moderate ED, no higher than 10 for severe ED, and 11 to 25 for mild and moderate ED. ED ¼ erectile dysfunction; LS ¼ least
squares.
172 Ralph et alin 1 patient and nasopharyngitis in 1 partner) were considered
unrelated to study treatment. There were no partner side effects
from direct contact with MED2005 with respect to pain or
burning on urination. No serious adverse events were reported
during the study, and there were no withdrawals from the study
because of adverse events. There were no clinically signiﬁcant
changes in blood pressure or electrocardiogram during the study.DISCUSSION
ED can markedly affect quality of life and psychological
well-being2,5,15,16 and can adversely affect female partners.17
Because there is evidence that the condition is oftenunderdiagnosed and undertreated,18,19 there is a clear unmet
need for new treatment strategies.6 The results of this phase II
study suggest that topical GTN formulated into a rapid and
efﬁcient delivery system (DermaSys) could offer a new option
for the treatment of ED.
Compared with placebo, MED2005 was associated with
signiﬁcantly greater increases in IIEF-EF score, which has been
shown to be a valid measure of ED severity.12 Furthermore, the
proportion of patients showing a clinically relevant increase in
IIEF-EF scores (4 points11) was signiﬁcantly larger with
MED2005 than with placebo. MED2005 also was associated
with signiﬁcant improvements in scores for the other IIEF do-
mains compared with placebo. These overall improvements wereJ Sex Med 2018;15:167e175
Table 3. Summary of patients’ responses* to SEP questions (full analysis set)
Percentage of “yes” responses†
LS mean ratio
(95% CI) P valueRun-in MED2005 Placebo
SEP question 1: “able to achieve at least some erection”
(n ¼ 229)
91.6 (18.5) 87.2 (26.5) 86.9 (26.2) 0.995 (0.96e1.03) .80‡
SEP question 2: “able to insert penis” (n ¼ 229) 74.9 (31.8) 75.5 (36.5) 75.4 (34.9) 0.99 (0.94e1.04) .67
SEP question 3: “erection lasts long enough” (n ¼ 229) 39.1 (34.0) 57.3 (39.4) 52.6 (38.8) 1.08 (0.99e1.17) .10‡
SEP question 4: “satisﬁed with hardness of erection”
(n ¼ 229)
17.1 (24.7) 42.9 (41.0) 29.0 (33.1) 1.52 (1.27e1.83) <.001
SEP question 5: “satisﬁed overall with this sexual experience”
(n ¼ 229)
27.0 (31.8) 48.2 (40.9) 36.9 (37.0) 1.32 (1.13e1.55) <.001
LS ¼ least squares; SEP ¼ Sexual Encounter Proﬁle.
*Partners’ responses were generally consistent with those of patients.
†Mean (SD).
‡Convergence of statistical model questionable.
Topical GTN in Treatment of Erectile Dysfunction 173driven by the patient subgroups with mild ED; no signiﬁcant
effect of MED2005 was seen in patients with moderate or severe
ED, although the study was not powered to detect a difference in
these subgroups. This could suggest that the GTN dose used in
this study, based on ﬁndings from a previous phase I pharma-
cokinetic study (unpublished data), was a minimally effective
dose.
MED2005 had a rapid onset of action in this study, with the
start of erection within 5 minutes in 44% of intercourse attempts
and within 10 minutes in almost 70%. This is in marked
contrast to oral PDE5 inhibitors, which typically have an onset
of action of 0.5 to 1.0 hour, and peak circulating drug concen-
trations are attained only 1 to 2 hours after administration.1,2
There was no signiﬁcant difference in onset time between
MED2005 and placebo gel, probably because the gel in the 2
treatments was massaged onto the glans penis for 15 seconds,
causing sexual stimulation. Importantly, no restrictions on food
or alcohol intake were imposed during this study. Hence, the
ﬁnding that an effect of MED2005 was observed within 5 to 10Table 4. Summary of adverse events (safety set)
Male patients
MED2005 (n ¼ 229) P
Any adverse event 55 (24.0%) 4
Serious adverse events 0
Adverse events leading to withdrawal 0
Mild adverse events 51 (22.3%) 3
Related 24 (10.5%)
Unrelated 32 (14.0%) 3
Moderate adverse events 5 (2.2%)
Related 0
Unrelated 5 (2.2%)
Severe adverse events 1 (0.4%)
Related 0
Unrelated 1 (0.4%)
J Sex Med 2018;15:167e175minutes in most patients suggests that food or alcohol intake has
no impact on the effectiveness of MED2005. By contrast, the
efﬁcacy of some oral PDE5 inhibitors, notably sildenaﬁl and
vardenaﬁl, is decreased after ingestion of fatty meals because of
delays in drug absorption from the gut.1,8,20,21
MED2005 was well tolerated compared with other topically
applied gels or PDE5 inhibitors. Adverse event rates of up to
78% have been reported in clinical trials with topical alprostadil
cream,22 and a meta-analysis of trials with PDE5 inhibitors re-
ported rates of 8.6% to 25.1%, depending on agent and dose.23
Most adverse events were mild or moderate, and there were no
serious adverse events during the study; indeed, no patient dis-
continued treatment because of adverse events. The most com-
mon adverse event, headache, occurred in only 18 patients
during treatment with MED2005 in 1,003 intercourse attempts
and was considered related to treatment in 14. There were only
isolated cases of vasodilator adverse events (mild tachycardia or
dizziness) and application site reactions, such as coldness or
irritation, and no cases of priapism. The incidence of adverseFemale partners
lacebo (n ¼ 227) MED2005 (n ¼ 229) Placebo (n ¼ 227)
2 (18.5%) 7 (3.1%) 3 (1.3%)
0 0 0
0 0 0
9 (17.2%) 6 (2.6%) 3 (1.3%)
8 (3.5%) 4 (1.7%) 1 (0.4%)
2 (14.1%) 2 (0.9%) 2 (0.9%)
4 (1.8%) 0 0
1 (0.4%) 0 0
3 (1.3%) 0 0
0 1 (0.4%) 0
0 0 0
0 1 (0.4%) 0
174 Ralph et alevents in female partners was extremely low (4 treatment-related
mild adverse events, including 2 mild headaches, in 1,003 in-
tercourse attempts), indicating that there is little or no trans-
ference of GTN to the female partner during intercourse or
during application of the gel by the female partner. Indeed, more
than 300 applications of MED2005 were performed by the
patient’s partner. There were no treatment-related partner side
effects such as pain or burning on urination.
In conclusion, the results of this phase II study suggest that
MED2005 is a potentially effective treatment for ED. Further
studies including higher doses of MED2005 are warranted to
improve clinical signiﬁcance, especially in cases of moderate and
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